Ownership and insider activity for Ligand Pharmaceuticals Incorporated (LGND): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions.
Price
| Price | $284.47 |
| Market Cap | $5.7B |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $141.0M | $201.7M | $718.4M | $71.5M | $47.6M | $19.5M | $45.0M | $23.0M | $72.3M | $174.9M |
| Short-term Investments | 0 | 0 | $46.2M | $998.3M | $363.6M | $321.6M | $166.9M | $147.4M | $183.9M | $558.6M |
| Receivables | $18.2M | $25.6M | $55.9M | $41.7M | $59.1M | $91.6M | $35.0M | $39.3M | $42.4M | $61.0M |
| Inventory | $1.9M | $4.4M | $7.1M | $7.3M | $26.5M | $27.3M | $13.3M | $24.0M | $14.1M | $9.1M |
| Total Current Assets | $163.1M | $237.0M | $870.5M | $1.12B | $500.6M | $464.8M | $263.6M | $237.4M | $331.6M | $832.3M |
| Property, Plant & Equipment | $1.8M | $4.2M | $5.4M | $17.6M | $37.2M | $32.6M | $27.5M | $25.1M | $24.8M | $10.8M |
| Goodwill | $276.9M | $314.5M | $306.4M | $95.2M | $189.7M | $105.7M | $105.7M | $103.4M | $105.2M | $101.5M |
| Intangible Assets | $25.8M | $19.5M | $31.5M | $230.5M | $606.3M | $386.8M | $352.6M | $299.6M | $266.6M | $422.3M |
| Total Assets | $601.6M | $671.0M | $1.26B | $1.49B | $1.36B | $1.30B | $762.7M | $787.2M | $941.8M | $1.56B |
| Accounts Payable | $2.7M | $2.3M | $4.2M | $2.4M | $3.8M | $8.4M | $5.3M | $2.4M | $5.2M | $3.2M |
| Short-term Debt | $212.9M | $224.5M | $26.4M | 0 | 0 | 0 | $76.7M | 0 | 0 | 0 |
| Total Current Liabilities | $227.1M | $238.9M | $82.2M | $17.0M | $100.1M | $41.7M | $98.8M | $16.8M | $37.1M | $37.4M |
| Long-term Debt | $29.6M | $18.9M | $609.9M | $639.0M | $442.3M | $320.7M | 0 | 0 | 0 | $446.2M |
| Total Liabilities | $230.7M | $252.4M | $699.9M | $727.7M | $652.8M | $476.4M | $165.2M | $86.3M | $111.3M | $543.4M |
| Retained Earnings | -$431.1M | -$400.9M | -$229.2M | $400.1M | $392.0M | $449.1M | $450.9M | $503.0M | $499.0M | $608.1M |
| Total Equity | $370.9M | $418.6M | $560.9M | $767.2M | $709.5M | $821.2M | $597.5M | $700.9M | $830.4M | $1.02B |
| Total Debt | $212.9M | $224.5M | $636.3M | $650.2M | $456.4M | $324.4M | $87.7M | $6.2M | $7.1M | $451.5M |
| Net Debt | $71.9M | $22.9M | -$128.3M | -$419.7M | $45.2M | -$16.7M | -$124.1M | -$164.1M | -$249.1M | -$282.0M |
| Working Capital | -$64.1M | -$1.8M | $788.3M | $1.11B | $400.4M | $423.1M | $164.8M | $220.6M | $294.4M | $794.8M |
Financial Health
| Debt / Equity | 1.17 |
| Current Ratio | 31.18 |
Profitability
| Gross Margin | 98.58% |
| Operating Margin | 34.74% |
| Net Margin | 67.88% |
Related companies: ACAD · ADMA · BLTE · CRNX · DYN · MIRM · NAMS
Explore sector: Healthcare · Biotechnology
More sections of LGND: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks